Oruka Therapeutics surges on positive Week 16 ORKA-001 psoriasis data

Oruka Therapeutics, Inc. (ORKA) is up 19.7% today. Here is some analysis on what might have caused this price movement.

Analysis: Shares appear to be rising after the company released positive Week 16 results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis. The update highlighted a strong complete skin clearance rate versus placebo and reinforced the drug’s long-acting profile, which investors may view as supportive of less-frequent dosing and a larger commercial opportunity.

Details:

Oruka released Week 16 data from the ongoing EVERLAST-A Phase 2a trial of ORKA-001 in plaque psoriasis in a company press release dated April 27, 2026.

The company reported that 63.5% of patients treated with ORKA-001 achieved PASI 100 (complete skin clearance) at Week 16, compared with 1 patient in the placebo arm.

The trial randomized 84 participants to receive two injections of ORKA-001 or placebo one month apart, with PASI 100 at Week 16 as the primary endpoint.

Oruka also pointed to pharmacokinetic/pharmacodynamic results that it believes support the potential for extended-interval maintenance dosing, with additional follow-up data expected later in 2026.

Sources:

GlobeNewswire, Fierce Biotech, Finviz

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ORKA Insider Trading Activity

$ORKA insiders have traded $ORKA stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.

Here’s a breakdown of recent trading of $ORKA stock by insiders over the last 6 months:

JOANA GONCALVES (Chief Medical Officer) has made 0 purchases and 15 sales selling 35,641 shares for an estimated $1,438,945.
LAURA LEE SANDLER (Chief Operating Officer) has made 0 purchases and 6 sales selling 18,600 shares for an estimated $563,396.
LAWRENCE OTTO KLEIN (Chief Executive Officer) sold 1,729 shares for an estimated $71,407
ARJUN AGARWAL (Senior Vice President, Finance) sold 395 shares for an estimated $16,313

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

$ORKA Hedge Fund Activity

We have seen 97 institutional investors add shares of $ORKA stock to their portfolio, and 29 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PARADIGM BIOCAPITAL ADVISORS LP added 1,710,316 shares (+inf%) to their portfolio in Q4 2025, for an estimated $51,839,677
CABLE CAR CAPITAL, LP removed 1,600,000 shares (-80.0%) from their portfolio in Q4 2025, for an estimated $48,496,000
BLACKROCK, INC. added 1,334,864 shares (+60.6%) to their portfolio in Q4 2025, for an estimated $40,459,727
BRAIDWELL LP removed 1,297,555 shares (-93.9%) from their portfolio in Q4 2025, for an estimated $39,328,892
STATE STREET CORP added 731,819 shares (+112.2%) to their portfolio in Q4 2025, for an estimated $22,181,433
VANGUARD GROUP INC added 676,865 shares (+38.1%) to their portfolio in Q4 2025, for an estimated $20,515,778
DEEP TRACK CAPITAL, LP removed 493,271 shares (-18.6%) from their portfolio in Q4 2025, for an estimated $14,951,044

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$ORKA Analyst Ratings

Wall Street analysts have issued reports on $ORKA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

UBS issued a "Buy" rating on 01/07/2026
BTIG issued a "Buy" rating on 11/13/2025
Jefferies issued a "Buy" rating on 11/13/2025

To track analyst ratings and price targets for $ORKA, check out Quiver Quantitative's $ORKA forecast page.

$ORKA Price Targets

Multiple analysts have issued price targets for $ORKA recently. We have seen 10 analysts offer price targets for $ORKA in the last 6 months, with a median target of $76.5.

Here are some recent targets:

Martin Fan from Wedbush set a target price of $85.0 on 04/15/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $70.0 on 04/13/2026
Yatin Suneja from Guggenheim set a target price of $125.0 on 04/13/2026
Julian Harrison from BTIG set a target price of $78.0 on 04/13/2026
Etzer Darout from Barclays set a target price of $78.0 on 04/07/2026
Michael Yee from UBS set a target price of $75.0 on 04/06/2026
David Risinger from Leerink Partners set a target price of $86.0 on 03/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.